Inhibrx reports promising OX40 immunotherapy results in head and neck cancer trials
Inhibrx announced that its experimental OX40-targeting immunotherapy showed activity in head and neck cancer patients, with especially strong responses in a small group with HPV-positive tumors.
The biotech firm said its OX40-focused drug produced measurable tumor responses among participants with head and neck cancer. The most notable outcomes were observed in a limited subset of patients whose cancers tested positive for HPV, suggesting a narrower applicability. This marks a rare success for a target that has eluded major companies such as Pfizer, Genentech, GSK and AstraZeneca for over a decade. CEO Mark Lappe described the achievement as gratifying after years of setbacks in the field. The data could influence future development strategies for OX40-based therapies.
Why it matters
It shows a rare breakthrough for a long-failed cancer target, potentially opening new treatment options for HPV-related head and neck tumors.
In this story
